We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

105 hedge funds and large institutions have $68.8M invested in Sanofi Contingent Value Rights in 2019 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 9

2% more funds holding

Funds holding: 103105 (+2)

7% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 15

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

6% less capital invested

Capital invested by funds: $73.1M → $68.8M (-$4.28M)

Holders
105
Holders Change
+2
Holders Change %
+1.94%
% of All Funds
2.27%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
13
Increased
16
Reduced
15
Closed
9
Calls
$15.8M
Puts
Net Calls
+$15.8M
Net Calls Change
+$616K

GCVRZ Hedge Fund Activity: Q1 2019 in Review

105 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q1 2019, worth a combined $68.8M — down 5.9% from $73.1M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new GCVRZ positions and 9 closed out — a net gain of 4 holders — while 16 added to existing stakes and 15 trimmed.

The largest buyer was Bardin Hill Management Partners, opening a new position worth an estimated $430K. The largest seller was UBS O'Connor, exiting entirely with an estimated $558K sold.

  • 105 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q1 2019, up from 103 in Q4 2018.
  • Funds reported $68.8M of Sanofi Contingent Value Rights stock for Q1 2019, down 5.9% quarter-over-quarter.
  • 13 funds opened new Sanofi Contingent Value Rights positions in Q1 2019 and 9 closed out, a net change of +4 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q1 2019 was Bardin Hill Management Partners, an estimated $430K added.
  • The largest Sanofi Contingent Value Rights seller in Q1 2019 was UBS O'Connor, an estimated $558K sold.

Based on aggregated 13F filings for Q1 2019.